The drug candidate was studied by Odyssey Thera as part of the ongoing collaboration with Pfizer. The achievement of this milestone is said to be the company’s first such milestone to be earned for contributing to the advancement of a drug candidate.
John Westwick, president and CEO of Odyssey Thera, said: “We are very pleased with the progress of the collaboration with Pfizer. Progress on this and other discovery programs with Pfizer demonstrates the power of our unique cellular analysis platform to improve knowledge of drug mechanisms and selectivity.”